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Long-term clinical studies of drug-eluting stents (DES) have reported high incidence of late thrombosis.
Given the growing concern over the clinical application of this technology, we have developed a stent
coated with bi-layered PLGA nanoparticles (BL-PLGA NPs) containing VEGF plasmid in the outer layer and
paclitaxel (PTX) in the inner core (VEGF/PTX NPs). We hypothesized that early release of VEGF gene
would promote re-endothelialization, while slow release of PTX would suppress smooth muscle cell
proliferation. Using Fc plasmid as a reporter gene, we observed that Fc/PTX NPs successfully expressed Fc
protein, but did not show cytotoxicity or anti-proliferative effect during the ﬁrst 7 days in cell culture. In
contrast, PTX NPs showed strong anti-proliferative effect staring from day 1 in culture, suggesting
sequential release of gene and PTX from the BL-PLGA NPs. In vivo effects of the treated stent were
assessed in mini-swines. Implantation of GFP/PTX NP-coated stents revealed efﬁcient local GFP gene
transfection at day 7. VEGF/PTX NP-coated stents showed complete re-endothelialization and signiﬁ-
cantly suppressed in-stent restenosis after 1 month compared to commercial DES. In conclusion, the
VEGF/PTX NP-coated stents promote early endothelium healing while inhibit smooth muscle cell
proliferation through sequential release of the VEGF gene and paclitaxel.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Cardiovascular disease is among the leading causes of disability
and mortality in modern society. Percutaneous coronary inter-
vention (PCI), including percutaneous transluminal coronary
angioplasty (PTCA) and stent implant, has been extensively devel-
oped and is currently the most frequently performed invasive
medical procedures in clinical practice [1,2]. However, a signiﬁcant
number of patients often develop restenosis after 3e6 months of
PCI operation [3,4] despite extensive “multidrug” anticoagulant
therapy. Drug-eluting stents (DES) have provided a breakthrough in
percutaneous treatment of coronary artery disease [5], especially
ones that are loaded with anti-proliferative agents such as PTX,
which target smooth muscle cell proliferation, have been shown to
effectively reduce the rate of in-stent restenosis. However, it has
also been suggested that the anti-proliferative drugs in DES inhibit3.
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C-ND license.endothelial cell growth resulting in delayed endothelium healing.
Long-term clinical studies of DES application frequently reported
cases of vascular smooth muscle cells (SMC) ﬁbrosis, endothelial
inﬂammation as well as late in-stent thrombosis [6,7].
Vascular homoeostasis is maintained by the endothelial cell (EC)
layer, which is involved in the regulation of platelet adhesion,
vasomotor function, and cell cycle quiescence of the cellular
constituents of the vascular wall [8]. Delayed re-endothelialization
and impaired endothelial function caused by DES implantationmay
be attributable to stent thrombosis and other adverse clinical
outcome observed following DES use [9]. In this regards, recent
studies and technologies have focused on enhancing the long-term
efﬁcacy and safety of DES by inhibiting maladaptive neointimal
proliferation while promoting re-endothelialization and repair. A
stem cell-capture stent, namely Genous Bio-engineered R-stent
(OrbusNeich), has been developed in order to improve endotheli-
alisation by coating the stent surface with an anti-CD34 antibody,
which can capture endothelial progenitor stem cells from the
peripheral blood [10]. However, the disadvantage of this approach
is that the CD34 antibodies are not speciﬁc to endothelial
Table 1
List of stents implanted in different groups of animals for in vivo studies on thera-
peutic effects.
Group no. of
animals
Stent name VEGF loading
(mg) on stent
PTX loading
(mg) on stent
Group 1 Bare 316L stent 0 0
Group 2 Blank NP stent 0 0
Group 3 PTX NP stent 0 30.66  4.30
Group 4 TAXUS stenta 0 w40
Group 5 VEGF NP stent 6.87  0.97 0
Group 6 VEGF/PTX NP stent 5.11  0.73 30.66  4.35
a Paclitaxel-Eluting Coronary Stents (TAXUS *stent) were purchased from
Boston Scientiﬁc Corporation.
Fig. 1. Schematic diagrams of material design and function hypothesis. (A), the structure of
pre-treated with laser beam which generates nano pores to increase the coating amount a
function. The sequential releasing pattern allows rapid re-endothelialization in the early da
J. Yang et al. / Biomaterials 34 (2013) 1635e16431636progenitor cells. Other haematopoietic stem cells can also be
captured by the CD34 antibody-coated stent and lead to increased
neointimal proliferation, whichmay contribute to the development
of in-stent thrombosis [11]. Therefore, studies of stent construction
using a combination of cell capture and DES technology, or other
speciﬁc antibodies are under investigation [12].
Vascular endothelial growth factor (VEGF) gene has been
extensively studied and used to promote revascularisation and re-
endothelialization by stimulating EPC migration and maturation
[13,14]. VEGF has attracted attention as a DES candidate for its
property in promoting endothelial regeneration while reducing in-
stent neointimal area in animal models [15]. Similarly, we have alsobi-layered VEGF/PTX NPs and procedures of stent coating. The bare metal stents were
nd stability. (B), assumed sequential release of VEGF/PTX and the mechanism of their
ys and later inhibition of smooth muscle cell proliferation.
J. Yang et al. / Biomaterials 34 (2013) 1635e1643 1637observed enhanced vascularisation in wound healing following
PLGA NPs-delivered therapeutic genes VEGF165 in limb ischaemia
[16], andmonocyte chemotactic protein-1 (MCP-1) in carotid artery
injury [17] in rabbits.
Poly (lactic-co-glycolic acid) (PLGA) is a biodegradable polymer
that has been approved by the FDA to be used in medicine and
medical devices. PLGA NPs have exhibited slow releasing capability
for hydrophobic drugs and have also been tested extensively for
DNA delivery in gene therapy [18,19]. Incorporation of NPs into
polymer coating layer on DES improved drug release proﬁles
[20,21]. Our previous study showed that stents coated with NPs of
DNA polyplexes could efﬁciently transfect and express the trans-
gene in stent-contacting arterial tissue, but not in adjacent arterial
segments or distal organs [22], suggesting the ﬂexibility of DNA NP
coated stents for localized gene delivery.
An ideal DES polymer should be non-thrombotic, non-inﬂam-
matory, and non-toxic and should facilitate vascular healing by
accelerating re-endothelialization. In an attempt to combine gene
therapy and DES drug delivery for effective inhibition of smooth
muscle cell proliferation while simultaneously promoting re-
endothelialization and repair, we have designed BL-PLGA NPs,
which contain a VEGF165 DNA plasmid in the outer layer and pacli-
taxel (PTX) in the inner core. These BL-PLGANPswere then coated to
laser beam pre-treated bare metal stents with an automatic spray
machine. We hypothesized that the BL-PLGA NPs would release the
angiogenesis gene and anti-proliferative drug in a sequential
manner to reduce the rate of late in-stent thrombosis following DES
implantation. Our stents were evaluated in a mini-swine coronary-
injury model. In order to assess the efﬁcacy and safety of our stent,
bare metal stents, stents coated with gene or drug free PLGA NPs,
stents coated with gene or drug alone PLGA NPs, and a commercial
DES (TAXUS) were used as controls in this study.
2. Materials and methods
2.1. Materials
VEGF165 plasmid with PCDNA3.0 vector as the backbone was a gift from Boqin
Qiang’s laboratory (Peking Union Medical College). Paclitaxel (PTX) was purchased
from Chongqing Meilian Company (Chongqing, China). PLGA (50/50, 60 000
molecular weight) was bought from Birmingham Polymers, Inc. (Birmingham, AL).
Polyvinyl alcohol (PVA) (Mw 30 000e70 000) was obtained from Sigma (St. Louis,
Missouri, USA). Micro-porous 316L stainless steel coronary stents (3.0  13 mm)
were purchased from Lepu Medical Technology Co. (Beijing, China). Fc plasmid was
constructed by Dr. Xiao-Qing Wei in Cardiff University previously Puriﬁed anti-Fig. 2. In vitro characterization of the Fc/PTX NPs for gene expression and cytotoxicity. (A), tr
The expression level increases as a function of time. (B), the growth curve of CHO cells in th
living cells after incubation for 7 days. Fc/PTX NPs are basically comparable to the controls in
Further increased cytotoxicity was observed at day 7, suggesting more release of PTX.human Fc antibody, hIgG standard and Bio-anti-Fc IgM were obtained from Pro-
tech and eBiosciences Inc. Plasmid encoding green ﬂuorescence gene (pGFP) was
purchased from Clontech (Palo Alto, CA, USA). All other chemicals were purchased
from Tianjin No.1 Chemical Reagent Factory (Tianjin, China).
2.2. Preparation of gene/PTX NPs
The BL-PLGA NPs containing DNA plasmid and PTX (gene/PTX NPs) with PTX in
the inner core and plasmid DNA in the outer layer were prepared by multi-step
emulsion technique. Firstly, PTX-PLGA NPs were prepared using a single emulsion
system [23]. Brieﬂy, PLGA and PTX were dissolved in dichloromethane and subse-
quently injected into a 2% aqueous solution of PVA under constant sonication to
form PTX-NPs. In next step, the dried PTX NPs were dispersed into an aqueous
solution of plasmid DNA (VEGF165, or Fc, or GFP) to form a composition of PTX NPs
entrapped in plasmid DNA matrix. The composition was then dispersed into PLGA/
dichloromethane solution using homogenizer to form a w/o emulsion. This w/o
emulsion was further added into an aqueous solution containing 2% (w/w) PVA
under stirring to form a w/o/w double emulsion with the PTX NPs entrapped by
plasmid DNA as the inner aqueous phase, that surrounded by PLGA/dichloro-
methane nano-droplets (the oil phase). The system was stabilized by the outer PVA
aqueous phase. In the ﬁnal step, the PLGA droplets were transferred into solid NPs by
removing the organic solvent. The NPs were collected by centrifugation and dried by
lyophilisation. The NPs were sterilised by gamma irradiation and stored at 4 C
before use. PTX-PLGA NPs, as well as blank PLGA NPs were also prepared in the same
way as controls. Rhodamine-PLGA NPs were prepared for the purpose of tracking.
2.3. Gene transfection in cell culture with Fc/PTX NPs
CHO cells were cultured in 24-well plates at 105 cells/well in FBS-free DMEM
medium overnight before co-incubating with 20 mg/ml Fc/PTX NPs. Fc NPs, PTX NPs,
blank PLGA NPs and complete DMEM, were separately incubated with cells in the
same way as controls. After 24 and 48 h, the cell culture supernatant was collected
and Fc protein expressionwas determined by ELISA. The amount of human IgG Fc in
cell culture medium was determined by sandwich ELISA (Protech and eBiosciences
Inc.) following the manufacturer’s instructions.
2.4. Cell viability assay
CHO cells were co-cultured with Fc/PTX NPs, Fc NPs, PTX NPs, and blank NPs,
respectively. Cell viability was measured by MTT assay following standard protocol.
The viable cell counts were determined based on the standards with known cell
number culture wells in triplicates.
2.5. Coating NPs on micro-porous 316L coronary stents
The bare 316L coronary stents were pre-treated with laser beam to create nano-
pores on the surface for NP loading. VEGF/PTX NPs were loaded onto the stent by
spray-coating. This was performed by dispersing the NPs in ethanol to form
a suspension and spray the NP suspension on the micro-porous stent with a medical
automatic spraying machine (Lepu Medical Technology Co., Beijing, China). The
amount of dry NPs coated on stent was determined by weight increase after NP
coating.ansfection of Fc NPs. Fc protein was only detected in Fc NPs or Fc/PTX NPs treated cells.
e presence of NPs. Cell growth was strongly suppressed by PTX NPs and there were no
terms of biocompatibility, although they began to showminimum cytotoxicity at day 2.
Fig. 3. Characterization of NPs coated stents. SEM images show the surface of bare metal stents (A, 100; A0 1000) and NPs coated stents (B, 100; B0 1000). The micro pores on
the surface of bare metal stents are speciﬁcally manufactured to improve polymer coating. After NPs coating, the micro pores were coved by particles. (C), Red ﬂuorescence of
rhodamine indicates successful coating of NPs onto the stents. The NP coating layer was stable. The ﬂuorescence intensity was decreased but it still remained after vigorous shaking
in PBS at 37 C for 30 days, suggesting the stability of NPs coating layer and its slow release (D). (E), the release curve of rhodamine from NPs coated stents. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
J. Yang et al. / Biomaterials 34 (2013) 1635e16431638
Fig. 4. In vivo examination of GFP expression 7 days after implantation. Gene transfection of nanopore coronary stent 7 days after implantation in vivo. Typical tissue slice observe
under ﬂuorescence microscope. (A), blank NPs coated stents; (B), GFP NPs coated stents (100).
J. Yang et al. / Biomaterials 34 (2013) 1635e1643 16392.6. Characterization of the morphology and stability of NPs coating layer
The surface structure of NP coating layer was determined by SEM observation.
Rhodamine B release kinetics of the NP coated stents were investigated by shaking in
phosphate-buffered saline (PBS) at 280RPM/minat37 C for 30days. The supernatant
was changed every another day for measurement of rhodamine concentration on
aﬂuorescence spectrophotometer. The remained rhodamine on the stent surfacewas
visualized under a Laser Scanning Confocal Microscope (ZEISS, LSM 710).
2.7. In vivo gene expression by the GFP/PTX NP-coated stents
All animal experiments were performed in compliance with the Guiding Prin-
ciples for the Care and Use of Laboratory Animals, Peking Union Medical College,
China. Each mini-swine weighing around 35 kg was given 150 mg Clopidogrel and
325 mg Aspiring orally 24 h before operation. Before the surgery, each animal
received an injection of 200 mg nitroglycerin to prevent thrombosis. During the
surgery, the animals were served with lowmolecular weight heparin for a total dose
of 150 IU/kg. The animals were sedatedwith 10mg/kg of azaperone intramuscularly,
anaesthetized with 10 mg/kg of thiopental intravenously. Anaesthesia was main-
tained with a continuous infusion of thiopental (5 mg/kg). The GFP/PTX NPs-coated
stentswere implanted into the left anterior descending coronary artery and the right
coronary artery of each mini-swine via 8F large lumen guiding catheters. Angiog-
raphy was performed to conﬁrm the stent’s position. After the surgery, each animal
was given 75 mg clopidogrel and 81 mg aspirin again. Euthanasia was performed
with ether 7 days after stent implantation. Arterial samples were frozen-sliced and
observed under ﬂuorescent microscope (Nikon Inc., Melville, NY, USA). GFP
expression in the stented artery was assessed with a ﬁlter calibrated to detect
ﬂuorescein isothiocyanate (FITC). Blank PLGA NP-coated stents were implanted and
evaluated in the same way as control.Fig. 5. Representative SEM images demonstrate the degree of re-endothelialization in each
NPs coated stent; (D), TAXUS stent; (E), VEGF NPs coated stent; (F), VEGF/PTX NPs coated2.8. In vivo therapeutic effects of VEGF/PTX NP-coated stents
The therapeutic effects of VEGF/PTX NP-coated stents were tested in mini-swine
coronary injury model. The in vivo experiments were performed at the Gateway
Medical Innovation Centre (Shanghai, China), which is an authorized platform of
preclinical and experimental study formedical device using large animal model with
qualiﬁed system and compliance to the highest international standards. The surgical
operator in this study owns licence awarded by FDA, USA for cardiovascular surgery
in large animals. Total six groups were involved in this set of experiments with 3
stents were implanted in each group (Table 1). The stents were implanted randomly
into the left anterior descending coronary artery (LAD), left circumﬂex artery (RCA)
and right coronary artery (LCX) of each mini-swine via 8F large lumen guiding
catheters. After stent implantation, all swine were given penicillin (4.8 million unit/
day) intramuscularly for up to 3 days while maintaining regular diet until be
executed. At 28 days after stent implantation, angiography was performed to
determine the rate of lumen loss. A computerized coronary angiography analysis
system (GE Company, Germany) was used to calculate the rate of lumen loss, which
was expressed as percentage of decrease in lumen diameter (LD) at follow-up. After
angiography, euthanasia was performed with ether and samples of arteries were
retrieved. Part of the arterial samples was ﬁxed by 10% formalin for pathological
section. Part of the samples was embedded in methylmethacrylate plastic. For
histochemical and morpholometric studies, the embedded artery samples were
sliced into 5 mm sections using a resin slicer (Merck, Darmstadt, Germany), stained
with haematoxylin and eosin (H&E), and examined by optical microscopy (CKX41-
A32PH, Olympus Co.). The lumen area and neointimal area were measured by
using computerized planimetry (Spot advanced 4; SPOT Imaging Solutions, Sterling
Heights, MI, USA). In order to observe endothelial morphology of the retrieved
arteries, part of the samples was ﬁxed in 2.5% gluteraldehyde and dehydrated in
gradient concentration of ethanol. The sample was mounted on a metal stub withgroup 28 days after implantation. (A), bare stent; (B), blank NPs coated stent; (C), PTX
stent (500).
J. Yang et al. / Biomaterials 34 (2013) 1635e16431640double-sided sticker and coated with gold using automated sputter coater before
observed by scanning electron microscopy (JSM-6360LV, JEOL Ltd, Japan).
2.9. Statistical analysis
Cell culture studies were carried out in replicates of three. Data for all experi-
ments are expressed as means  SEM and analysed using t-test or analysis of
variance (ANOVA) when appropriate. All statistical analyses were performed with
SPSS V 13.0. Differences between groups were considered signiﬁcant when the
probability of the calculated statistic was less than 0.05.
3. Results
3.1. Design of bi-layered VEGF/PTX NPs and their use in stent coating
The design of bi-layered VEGF/PTXNPs, their use in stent coating
and the hypothesis of this study are illustrated in Fig. 1. With VEGF
plasmid loaded in the outer layer of PLGA NPs and PTX in the inner
core, we expected the release of VEGF gene and PTX in a sequential
manner. PLGA NPs were sprayed and adhered onto the surface of
bare metal stents by an automatic spraying machine. In order to
increase the loading amountof PLGANPs, the baremetal stentswere
treated with laser beam to create a rough surface with nano pores.Fig. 6. Representative angiographic images demonstrate lumen loss 28 days after implantation
(E), VEGFNPs coated stent; (F), VEGF/PTXNPs coated stent.White arrows indicate the proximaThe ideal sequential release of VEGF and PTX, their effect on
endothelial cells and smoothmuscle cells are illustrated in Fig.1B. In
the early days after stents implantation, VEGF plasmid could be
observed to release from the NPs coated stents and transfect local
tissues. The transgene would express VEGF and promote rapid re-
endothelialization. Following the release of VEGF gene, PTX will
eventually diffuse from the NPs core and release from the stent to
suppress the growth of smoothmuscle cells. There is a timewindow
between the release of VEGF and PTX that may allow formation of
the endothelium.
3.2. .In vitro analysis of the release kinetics and the function of gene
and paclitaxel
Human IgG Fc expressing gene vector and PTX were co-
encapsulated into bi-layered PLGA NPs for the purpose of in vitro
analysis. As shown in Fig. 2A, Fc protein secretionwas conﬁrmed by
ELISA assay 24 h after incubation. The Fc protein secretory level
was found to increase signiﬁcantly only after 48 h in the Fc NP or
Fc/PTX NP treated cells, suggested successful release and trans-
fection of the Fc gene loaded PLGA NPs. The toxicity and anti-
proliferative effect of Fc/PTX NPs were evaluated by MTT assay.. (A), bare stent; (B), blankNPs coated stent; (C), PTXNPs coated stent; (D), TAXUS stent;
l,middle anddistal sites of stented arteries for digital record and calculation of lumen loss.
J. Yang et al. / Biomaterials 34 (2013) 1635e1643 1641As shown in Fig. 2B, cell growth was strongly suppressed by PTX
NPs and there were no living cells after 7 days incubation. In
contrast, Fc/PTX NPs showed no cytotoxicity in the ﬁrst 24 h with
minimum cytotoxicity detectable at day 2. A signiﬁcant increase of
cytotoxicity was observed at day 7, indicating increased release of
PTX. It is worth noting that Fc/PTX NPs and PTX NPs exhibited
different anti-proliferative effects during the 7-day cell culture
experiment.
3.3. Characterization of the NPs coated stents
SEM images showed that the bare stent has micro pores on
the surface, which were manufactured speciﬁcally for improving
polymer coating (Fig. 3A and A’). Coating with NPs generated
a smoother surface compare to the bare stents. The observed
particles on the surface may be aggregates of NPs (Fig. 3B and
B’). Red ﬂuorescence of Rhodamine indicates successful coating
of NPs onto the stents (Fig. 3C). The stability of NP coating layer
and the release of drug from the stent were determined by
ﬂuorescence quantiﬁcation of Rhodamine. The ﬂuorescence
intensity of Rhodamine showed a tendency of decline but
remained at detectable level (Fig. 3D) after vigorous shaking in
PBS at 37 C for 30 days, suggesting the stability of NPs coating
layer and its slow release (Fig. 3E). The amount of dry NPs
coated on stent was determined by weight increase after NP
coating. The loading amount of gene and drug were listed in
Table 1.
3.4. In vivo analysis of transgene expression of GFP NPs coated stents
In order to visualize gene expression of the gene/PTX coated
stent in vivo, green ﬂuorescence protein (GFP) gene was also
incorporated as a report gene. GFP/PTX NPs were prepared and
coated onto stents. 7 days after implantation in mini-swine coro-
nary arteries, sections of harvested arterial tissue showed strong
green ﬂuorescence under the ﬂuorescence microscope (Fig. 4B). No
ﬂuorescence signal was detectable in the control stent group
(Fig. 4A). This data further conﬁrmed that our gene/PTX NP coated
stents can realize localized gene therapy.Fig. 7. Representative images of H&E staining of cross-sections 28 days after implantation. (A
(E), VEGF NPs coated stent; (F), VEGF/PTX NPs coated stent. (40).3.5. VEGF/PTXNPcoatedstentspromoted re-endothelialization invivo
After implantation for 28 days, the progress of re-
endothelialization was examined by SEM. As shown in Fig. 5, the
surface of bare metal stents (Fig. 5A) and empty NPs coated stents
(Fig. 5B) are partially covered with cobblestone-like endothelial
cells. There is no endothelial cells, only ﬁbrotic tissues on the
surface of PTX NP coated stents (Fig. 5C). The commercial DES,
TAXUS stents are covered with cells, which did not exhibit typical
endothelial phenotype (Fig. 5D). In contrast, both VEGF NP and
VEGF/PTX NP coated stents are covered with conﬂuent endothelial
layer (Fig. 5E and F). These data suggest that re-endothelialization
was enhanced in animals treated with VEGF coated stents, but
suppressed in PTX coated groups. Re-endothelialization of the bi-
layered NP coated stents was not affected by the loaded PTX.3.6. VEGF/PTX bi-layered NP coated stents reduced in-stent
restenosis and luminal loss
In-stent restenosis was examined by angiographic and
morphological analysis. Angiographic images are shown in Fig. 6.
There are no signs of stent malapposition in all groups. The rate of
lumen loss calculated by lumen diameters was 22.3  2.3% in
VEGF/PTX NP stents, 25.2  2.5% in VEGF NP stents, 48.0  9.8% in
bare stents, 40.0  4.6% in blank NP stents, 48.0  3.7% in PTX NP
stents, and 48.0  4.8% in TAXUS stents, respectively. Lumen loss
in both VEGF loaded groups is signiﬁcantly smaller than other
groups (p < 0.05) (Fig. 8A).
H&E staining of cross sections are shown in Fig. 7. The thickness
of neointimal formation is greater in the bare and blank NPs coated
stents than the medium neointimal formation observed in either
PTX NP coated stents or commercial TAXUS stent. However, little
neointimal formation was observed in both VEGF NPs and VEGF/
PTX NP coated groups.
Lumen areas were calculated based on the H&E staining images.
It is 3.708 0.839mm2 inVEGF/PTXNP stents, 3.0891.164mm2 in
VEGFNP stents,1.0090.281mm2 in bare stents,1.4110.707mm2
in blank NP stents, 2.310  0.289 mm2 in PTX NP stents, and
2.125  0.022 mm2 in TAXUS stents, respectively (Fig. 8B).), bare stent; (B), blank NPs coated stent; (C), PTX NPs coated stent; (D), TAXUS stent;
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J. Yang et al. / Biomaterials 34 (2013) 1635e16431642Similarly, the rate of restenosis in the 6 groups are as follows:
VEGF/PTX NP stents 28.9  1.3%, VEGF NP stents 40.4  3.0%, bare
stents 77.2  7.8%, blank NP stents 53.0  7.4%, PTX NP stent
52.5  2.0%, TAXUS stent 57.1  0.7% (Fig. 8C).
4. Discussion
Drug-eluting stent (DES) has been demonstrated to be more
effective than bare metal stents in reducing vascular restenosis by
suppressing smooth muscle cell proliferation. However, the anti-
proliferative agents released by DES also inhibit endothelial cell
growth resulting in delayed endothelium healing [24]. Long-term
clinical studies regarding DES application frequently reported
cases of vascular smooth muscle cells (SMC) ﬁbrosis, endothelial
inﬂammation as well as late in-stent thrombosis [7,25,26], which
raised concerns over the future of clinical DES application.
In this study, we tested the hypothesis that if endothelium
healing is promoted in the early stage of vascular endothelial
injury soon after the PTCA operation but before the release of
drugs which suppress smooth muscle cell proliferation, it may be
possible to block the pathological process of in-stent restenosis
(ISR) and late in-stent thrombosis. VEGF-a family peptide has been
used to promote revascularisation and re-endothelialisation by
stimulation endothelium progenitor cells (EPC) migration and
maturation [13,27], which presents as a potential candidate for
vascular endothelial gene therapy. Based on these pathogenesis
and treatment strategy of restenosis, we designed a gene/drug co-
delivery stent, which can release a VEGF expressing gene vector
and paclitaxel in a sequential manner, i.e. an early release of VEGF
gene to promote rapid re-endothelialization followed by a sus-
tained release of paclitaxel to inhibit smooth mussel proliferation.
This design was achieved by coating metal stent with bi-layered
PLGA NPs that contained VEGF plasmid in the outer layer and
paclitaxel in the core.
In order to prove that this bi-layered PLGA NP delivery system
can sequentially release VEGF and paclitaxel, a human IgG Fc
expression plasmid was selected as reporter plasmid. The Fc/PTX-
loaded bi-layered PLGA NPs were successfully constructed. Results
generated by ELISA showed that cells transfected with Fc/PTX NPs
expressed Fc protein (Fig. 2A), suggesting successful release and
transfection of the encapsulated Fc gene in PLGA NPs. Cell viability
was assessed by MTT assays in order to test inhibitory effect of Fc/
PTX NPs on cell growth. As expected, Fc/PTX NPs showed no
cytotoxicity in the ﬁrst 24 h. Minimal cytotoxicity was observed
after 48 h and remained at similar level until a signiﬁcant increase
of toxicity observed at day 7, indicating a delayed release of
paclitaxel. As control group, the paclitaxel-only PLGA NPs showed
signiﬁcant inhibition on cell growth at the start of the ﬁrst 24 h.
These results suggested a sequential gene and paclitaxel releasing
pattern from the bi-layered PLGA NPs. Based on these in vitro
studies, we speculate that VEGF gene in the outer-layer of the NP
would be released ﬁrst and promote an early endothelium healing
followed by the later release of paclitaxel from the inner core of
the NP, which could maintain a sustained inhibitory effect on
smooth muscle cell proliferation.
In order to visualize the gene delivery process and the
expression of the gene/PTX loaded stent in vivo, we used green
ﬂuorescence protein (GFP) gene as a reporter and prepared GFP/
PTX NP coated stents. 7 days after implantation in mini-swine
coronary arteries, tissue sections showed strong GFP signals
under a ﬂuorescence microscope, again conﬁrming that our gene/
drug NPs coated stents can realize localized gene therapy. Ther-
apeutic evaluation tests were carried out in regular intervals up
to 28 days. SEM results revealed complete endothelium forma-
tion in the group of VEGF/PTX NP coated stents, and the loss of
J. Yang et al. / Biomaterials 34 (2013) 1635e1643 1643arterial lumen was signiﬁcantly smaller than the other treatment
groups. Based on these results, we propose that the VEGF gene was
ﬁrst released from the bi-layered NPs and transfected surrounding
tissues, which lead to production of VEGF protein and conse-
quently rapid endothelialisation. Studies have demonstrated that
regenerated endothelium was able to modulate vascular tension,
inhibit thrombosis formation and smooth muscle cell proliferation
through the production of nitric oxide [28,29]. Our in vivo exper-
iments showed similar anti-restenosis effects from the VEGF alone
and VEGF/PTX loaded stent groups, which are superior to the
stents in other non-VEGF groups. This observation may suggest
that VEGF gene therapy played a major role during the ﬁrst 28 days
after DES treatment. The rapidly repaired endothelium may act as
a natural barrier to inhibit leukocytes and platelet adhesion, and
thus prevent late thrombosis formation [26]. Paclitaxel eluting
stents have been demonstrated to strongly inhibit cell prolifera-
tion, adhesion and migration including endothelial cells, and
therefore delayed the re-endothelialization process [30,31]. In our
gene/drug sequential release system, VEGF gene in the outer layer
was released ﬁrst. The outer VEGF-PLGA layer also acts as a barrier
that prevents early release of paclitaxel. Later on, due to the
degradation of outer VEGF-PLGA layer, paclitaxel began to release
and take effect on the smooth muscle cells. The present study has
demonstrated signiﬁcant anti-restenosis effects of the VEGF/PTX
NP coated stents in vivo, however further experiments are required
to evaluate long-term effects of these stents for clinical use.
5. Conclusion
In this paper, we reported a gene and drug co-delivering coro-
nary stent coated with bi-layered PLGA NPs, which contained
a VEGF plasmid in the outer layer and PTX in the inner core. The
VEGF/PTX NPs were successfully coated by spray-coating tech-
nology on metal coronary stents that have been pre-treated to have
nonporous surface. In vitro experiments and in vivo animal studies
both conﬁrmed that the system could promote early endothelium
healing and inhibit smooth muscle cell proliferation through
sequential release of selected genes and drugs. Our data suggest
that the VEGF/PTX NP coated coronary stent may be a promising
approach for the prevention and treatment of vascular restenosis.
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